Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q3 2019 · 10-Q
Revenue$567.00K$567.00K−42.3% vs Q3 2018 Net Income-$16.51M-$16.51MN/M vs Q3 2018 EPS Diluted-$0.11-$0.11N/M vs Q3 2018 Gross Profit$453,000−52.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$7,443,000N/M Free Cash Flowderived-$7,512,000N/M Margins · derivedGross margin79.9%−16.5 pt vs Q3 2018
Operating margin-1485.4%−430.7 pt vs Q3 2018
Net margin-2910.9%
ended Sep 30, 2019 · filed Nov 12, 2019 · 43 d after period end